NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: PGHL · data 2026-10-31
Procter & Gamble Health Ltd.
In plain words
Price: 18.7% below its 52-week high of ₹6,975.
Delivery: 57.2% of traded shares were kept for delivery over the last 10 sessions, against 56.0% over the last 60.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹1,408 cr |
| Net profit (last 12 months) | ₹327 cr |
| Sales growth, 3 years (yearly) | 8.2% |
| Profit growth, 3 years (yearly) | 19.3% |
At a glance
Promoters 51.8% (unchanged in a year), pledged 0.0%, institutions 19.1%.
P/E 28.8, P/B 17.9, dividend yield 2.7%. Price relative to earnings and book value (low is cheaper, not better).
ROE 61.6%, ROCE 75.7%, operating margin 30.8%: how much profit it earns on the money it uses.
Debt/equity 0.02, Profit growth 19.3% and sales growth 8.2% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
- High return on equity (61.6%).
- Healthy operating margin (30.8%).
- Profit grew 19.3% a year over 3 years.
- Pays a dividend yielding 2.7%.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Earnings call in brief (18 Jun 2026)
- Management said sales for the 12‑month fiscal year ended March 31 2026 were close to ₹1400 crore, up 16% versus the comparable period last year.
- Management said profit after tax was ₹327 crore, up 30% versus the comparable period last year.
- Management said the company delivered Rs. 35 crore of savings in the last year through targeted productivity and savings programs.
- Management said new product launches this year included Livogen Iron Gummies, Neurobion Nerve Pain Relief Cream and Evion L5000, and that Livogen Iron Gummies achieved the #1 category share on Amazon.
- Management said they will continue to invest in product innovation, superior brand communication, retail execution across physical and digital channels, and expand coverage in extra‑urban areas, while monitoring risks from market volatility and cost pressures.
- प्रबंधन ने कहा कि 31 मार्च 2026 को समाप्त 12‑महीने के वित्तीय वर्ष की बिक्री लगभग ₹1400 करोड़ थी, जो पिछले वर्ष की तुलना में 16 % बढ़ी है।
- प्रबंधन ने कहा कि कर पश्चात लाभ ₹327 करोड़ था, जो पिछले वर्ष की तुलना में 30 % बढ़ा है।
- प्रबंधन ने कहा कि कंपनी ने पिछले वर्ष लक्षित उत्पादकता और बचत कार्यक्रमों के माध्यम से Rs. 35 करोड़ की बचत हासिल की।
- प्रबंधन ने कहा कि इस वर्ष के नए उत्पाद लॉन्च में Livogen Iron Gummies, Neurobion Nerve Pain Relief Cream और Evion L5000 शामिल हैं, और Livogen Iron Gummies ने Amazon पर श्रेणी में #1 शेयर हासिल किया।
- प्रबंधन ने कहा कि वे उत्पाद नवाचार, श्रेष्ठ ब्रांड संचार, भौतिक और डिजिटल दोनों चैनलों में रिटेल निष्पादन, और अतिरिक्त‑शहरी क्षेत्रों में कवरेज का विस्तार जारी रखेंगे, साथ ही बाजार अस्थिरता और लागत दबाव से जुड़े जोखिमों की निगरानी करेंगे।
- મેનેજમેન્ટે કહ્યું કે 31 માર્ચ 2026ને સમાપ્ત થયેલા 12‑મહિના નાણાકીય વર્ષ માટેની વેચાણ લગભગ ₹1400 કરોડ હતી, જે ગયા વર્ષની તુલનામાં 16 % વધેલી છે.
- મેનેજમેન્ટે કહ્યું કે કર પછીનું નફો ₹327 કરોડ હતો, જે ગયા વર્ષની તુલનામાં 30 % વધ્યો છે.
- મેનેજમેન્ટે કહ્યું કે કંપનીએ ગયા વર્ષમાં લક્ષિત પ્રોડક્ટિવિટી અને બચત કાર્યક્રમો દ્વારા Rs. 35 કરોડની બચત મેળવી.
- મેનેજમેન્ટે કહ્યું કે આ વર્ષના નવા પ્રોડક્ટ લોન્ચમાં Livogen Iron Gummies, Neurobion Nerve Pain Relief Cream અને Evion L5000 શામેલ છે, અને Livogen Iron Gummiesએ Amazon પર કેટેગરીમાં #1 શેર મેળવ્યો છે.
- મેનેજમેન્ટે કહ્યું કે તેઓ પ્રોડક્ટ ઇનોવેશન, શ્રેષ્ઠ બ્રાન્ડ કમ્યુનિકેશન, ભૌતિક અને ડિજિટલ ચેનલોમાં રિટેલ એક્ઝિક્યુશન, અને વધારાના‑શહેરી વિસ્તારોમાં કવરેજનું વિસ્તરણ ચાલુ રાખશે, સાથે સાથે બજારની અસ્થિરતા અને ખર્ચ દબાણ સંબંધિત જોખમોની દેખરેખ રાખશે.
What management said on the call, summarised by AI from the official transcript and checked against it. Read the transcript. Not a recommendation.
Smart-money activity
20/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 7/30: Delivery 58.6% over the last 20 sessions vs 47.4% in the 40 before (1.24x); shares delivered per day 0.8x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 8/15: Verdict "Building", sustained score 45/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Dividend
- 27 Aug 26Dividend Dividend ₹45 (ex-date) -1.7% next session
- 12 Feb 26Dividend Dividend ₹110 (ex-date) -9.0% next session
- 22 Aug 25Dividend Dividend ₹45 (ex-date) +1.2% next session
- 21 Feb 25Dividend Dividend ₹80 (ex-date) -3.3% next session
- 28 Nov 24Dividend Dividend ₹60 (ex-date) -0.6% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 51.82% | 51.82% | 51.82% | 51.82% |
| Foreign institutions (FII) | 6.42% | 6.33% | 6.20% | 6.97% |
| Domestic institutions (DII) | 12.63% | 12.44% | 13.67% | 13.84% |
| Mutual funds | 8.89% | 9.05% | 10.20% | 10.48% |
| Retail investors | 21.54% | 21.60% | 21.31% | 20.57% |
| Number of shareholders | 50,426 | 49,056 | 50,883 | 49,302 |
Common questions
How much do promoters hold in Procter & Gamble Health Ltd.?
Promoters held 51.82% of Procter & Gamble Health Ltd. at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Procter & Gamble Health Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.02, which is very low.
What is Procter & Gamble Health Ltd.'s P/E ratio?
About 28.8, based on the last 12 months' earnings and a price of ₹5,670.5 (data 2026-10-31).
What is the 52-week high and low of Procter & Gamble Health Ltd.?
The 52-week high is ₹6,975 and the 52-week low is ₹4,707.
Mutual funds holding Procter & Gamble Health Ltd.
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 4 schemes holding about ₹113 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| ADITYA BIRLA SUN LIFE MNC FUND | Aditya Birla Sun Life Mutual Fund | 1.74% | ₹53 cr |
| ADITYA BIRLA SUN LIFE CONSUMPTION FUND | Aditya Birla Sun Life Mutual Fund | 0.43% | ₹25 cr |
| ADITYA BIRLA SUN LIFE PHARMA & HEALTHCARE FUND | Aditya Birla Sun Life Mutual Fund | 1.82% | ₹20 cr |
| ADITYA BIRLA SUN LIFE BUSINESS CYCLE FUND | Aditya Birla Sun Life Mutual Fund | 0.92% | ₹16 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Procter & Gamble Health Ltd. | ₹5,670.5 | ₹9,436 cr | 28.8 | 17.9 | 61.6% | 75.7% | 0.02 | -8.3% |
| Strides Pharma Science Ltd | ₹1,068.8 | ₹9,855 cr | 16 | 2.9 | 19.7% | 15.1% | 0.57 | +24.7% |
| Viyash Scientific Limited | ₹218.39 | ₹9,644 cr | 53.4 | — | 9.8% | 12.4% | 0.17 | +2.0% |
| Blue Jet Healthcare Limited | ₹504.55 | ₹9,547 cr | 37.3 | — | 19.9% | 21.1% | 0.03 | -22.9% |
| Symbiotec Pharmalab Limited | ₹1,246.3 | ₹8,001 cr | — | — | — | — | — | +26.1% |
| Aarti Pharmalabs Limited | ₹872.7 | ₹7,922 cr | 30.9 | 3.5 | 8.5% | 11.5% | 0.36 | +4.9% |
Compare PGHL with STAR in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open PGHL in NSE Scanner →